Raia Drogasil SA
OTC:RADLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (36.6), the stock would be worth $5.48 (25% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 29.3 | $4.39 |
0%
|
| 3-Year Average | 36.6 | $5.48 |
+25%
|
| 5-Year Average | 40.7 | $6.09 |
+39%
|
| Industry Average | 9.5 | $1.42 |
-68%
|
| Country Average | 9.9 | $1.49 |
-66%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$38.2B
|
/ |
Jan 2026
R$1.3B
|
= |
|
|
$38.2B
|
/ |
Dec 2026
R$1.8B
|
= |
|
|
$38.2B
|
/ |
Dec 2027
R$2.3B
|
= |
|
|
$38.2B
|
/ |
Dec 2028
R$2.7B
|
= |
|
|
$38.2B
|
/ |
Dec 2029
R$3B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| BR |
|
Raia Drogasil SA
OTC:RADLY
|
38.5B USD | 29.3 | |
| ZA |
C
|
Clicks Group Ltd
JSE:CLS
|
62.2B ZAR | 19.2 | |
| ZA |
D
|
Dis-Chem Pharmacies Ltd
JSE:DCP
|
30.9B ZAR | 25 | |
| US |
|
Walgreens Boots Alliance Inc
NASDAQ:WBA
|
10.4B USD | -1.6 | |
| JP |
|
Tsuruha Holdings Inc
TSE:3391
|
974.6B JPY | 22.8 | |
| JP |
|
MatsukiyoCocokara & Co
TSE:3088
|
944.5B JPY | 16.9 | |
| SA |
|
Al Nahdi Medical Company SCJSC
SAU:4164
|
16.8B SAR | 20.2 | |
| JP |
|
Welcia Holdings Co Ltd
TSE:3141
|
657.7B JPY | 34.3 | |
| CN |
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
28B CNY | 16.2 | |
| JP |
S
|
Sugi Holdings Co Ltd
TSE:7649
|
587.3B JPY | 13.1 | |
| CN |
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
21.4B CNY | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.3 |
| Median | 9.9 |
| 70th Percentile | 13.5 |
| Max | 842.8 |
Other Multiples
Raia Drogasil SA
Glance View
Raia Drogasil SA, Brazil's pharmaceutical titan, stands as a testament to the transformative power of strategic mergers and innovative retail management. Born out of the merger of Drogasil and Droga Raia, two of Brazil's enduring pharmacy chains, the company today operates an extensive network of retail stores across the nation. This strategic merger in 2011 was not merely a consolidation of operations but a fusion of distinct corporate cultures and expertise, aimed at enhancing operational efficiencies and expanding market share. By leveraging economies of scale, Raia Drogasil has entrenched itself as a formidable force in Brazil's healthcare retail sector, boasting a strong presence in both high-density urban centers and emerging markets in Brazil. The company's business model is built on a robust mix of health and wellness products, encompassing everything from prescription medications to over-the-counter remedies and personal care items. Raia Drogasil has adeptly positioned itself to capitalize on Brazil's growing healthcare demands, thanks to its comprehensive product offerings and strategic store locations. Each store functions as both a destination for health-conscious consumers and a vital link in the greater logistical chain that ensures timely product availability. By intertwining brick-and-mortar retail with digital innovation, Raia Drogasil not only drives revenue through traditional sales channels but also through its dynamic e-commerce platform. This synergy allows the company to tap into the evolving preferences of tech-savvy consumers, thereby making Raia Drogasil a leader in seamlessly integrating shopping experiences that cater to modern customer expectations.